Cancer cells acquire several traits that allow for their survival and progression, including the ability to evade the host immune response. However, the mechanisms by which cancer cells evade host immune responses remain largely elusive. Here we study the phenomena of immune evasion in malignant melanoma cells. We find that the tumor suppressor phosphatase and tensin homolog (PTEN) is an important regulator of the host immune response against melanoma cells. Mechanistically, PTEN represses the expression of immunosuppressive cytokines by blocking the phosphatidylinositide 3-kinase (PI3K) pathway. In melanoma cells lacking PTEN, signal transducer and activator of transcription 3 activates the transcription of immunosuppressive cytokines in a PI3K-dependent manner. Furthermore, conditioned media from PTEN-deficient, patient-derived short-term melanoma cultures and established melanoma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendritic cells. Inhibition of IL-12 production was rescued by restoring PTEN or using neutralizing antibodies against the immunosuppressive cytokines. Furthermore, we report that PTEN, as an alternative mechanism to promote the host immune response against cancer cells, represses the expression of programmed cell death 1 ligand, a known repressor of the host immune response. Finally, to establish the clinical significance of our results, we analyzed malignant melanoma patient samples with or without brisk host responses. These analyses confirmed that PTEN loss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses compared with samples with brisk host responses. Collectively, these results establish that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response against melanoma cells and highlight the importance of assessing PTEN status before recruiting melanoma patients for immunotherapies.
INTRODUCTION
Phosphatase and tensin homolog (PTEN) is a known tumor suppressor that is frequently inactivated in a variety of human cancers, including melanoma. 1, 2 Up to one-third of melanomas have been shown to have mutational inactivation or deletion of PTEN. 2 PTEN is a lipid phosphatase that negatively regulates the phosphatidylinositide 3-kinase (PI3K) pathway. Therefore, PTEN loss constitutively activates the PI3K pathway and has been shown to have an important role in melanoma. 2 For example, PTEN loss cooperates with oncogenic NRAS and BRAF mutations to cause melanomagenesis and promote melanoma progression. [3] [4] [5] To prevent melanomagenesis, normal melanocytes exert tumor suppressive mechanisms, which act as a barrier to neoplastic transformation and cancer progression. 6, 7 Of the previously identified cell non-autonomous tumor suppression mechanisms, the host immune response against tumor cells is one of the most important. Expression of tumor-specific antigens, which is a consequence of genetic and epigenetic changes, makes tumor cells vulnerable to the host immune response. Therefore, for cancer cells to survive and proliferate, they must evolve strategies to evade and/or suppress the host immune response. 8 Immune evasion is often associated with metastatic spread, a major concern in melanoma. 9, 10 Immune evasion strategies employed by cancer cells include immunomodulatory and immune subversive strategies. 8 An understanding of these strategies is essential in designing effective immune-based therapies that specifically target the ability of tumors to escape host immunity.
In this study, we evaluated whether PTEN expression in melanoma cells regulates the ability of these cells to evade the host immune response. First, we show that PTEN negatively regulates the expression of immunosuppressive cytokines and programmed cell death 1 ligand (PD-L1) in a PI3K pathwaydependent manner. Next, we report that melanoma cells lacking PTEN expression exert a strong immunosuppressive effect. Finally, we analyzed samples from patients with malignant melanoma with or without brisk host responses. We report that malignant melanoma samples lacking brisk host responses showed a higher tendency to lose PTEN expression compared with samples with brisk host responses. Collectively, our results show that PTEN functions as a tumor suppressor in melanoma in part by promoting the host immune response against melanoma cells.
RESULTS

Loss of PTEN leads to transcriptional activation of immunosuppressive cytokines in a PI3K pathway-dependent manner
We hypothesized that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response. Previous studies have established a role for immunosuppressive cytokines in inhibiting the host immune response and have shown that they might be important for immune evasion by cancer cells. [11] [12] [13] Therefore, we first tested whether PTEN negatively regulates the expression of immunosuppressive cytokines. We analyzed the mRNA expression of the immunosuppressive cytokines interleukin IL-10, IL-6 and vascular endothelial growth factor (VEGF) in the PTEN-defective cell line SKMEL-28, which was engineered to express PTEN under a tetracycline-responsive promoter (SKMEL-28/PTEN-Tet-OFF; Figure 1a) . The results presented in Figures 1b and c show that PTEN expression transcriptionally repressed IL-10, IL-6 and VEGF expression in a dosedependent manner. PTEN is a non-redundant, plasma membrane lipid phosphatase that antagonizes the PI3K pathway by hydrolyzing the 3 0 -phosphate of 3,4,5-triphosphate. 14 Therefore, we evaluated whether the ability of PTEN to repress immunosuppressive cytokine expression depends upon its ability to inhibit the PI3K pathway. To test this, we treated PTEN-mutant SKMEL-28 cells with the PI3K inhibitor LY294002 and monitored the expressions of IL-10, IL-6 and VEGF transcripts. As expected, treatment of SKMEL-28 cells with LY294002 blocked AKT phosphorylation, which is the major downstream effector of PI3K (Figure 1d) . Notably, inhibition of the PI3K pathway inhibited transcriptional activation of IL-10, IL-6 and VEGF (Figures 1e and f) . To further generalize our findings, we analyzed two additional PTEN-deficient melanoma cell lines (UACC62 and A2058) that were engineered to constitutively express PTEN (Figure 1g ). In good agreement with our results in SKMEL-28 cells, we observed that PTEN expression was sufficient to inhibit the expression of IL-10, IL-6 and VEGF (Figures 1h and i) . To further confirm whether PI3K is necessary for the upregulation of the immunosuppressive cytokines in these cell lines, we treated the parental cell lines UACC62 and A2058 with the PI3K inhibitor LY294002 (Figure 1j ). The results presented in Figures 1k and l show that similar to PTEN expression, inhibition of the PI3K pathway in UACC62 and A2058 cells inhibited the expression of IL-10, IL-6 and VEGF. Collectively, these results demonstrate that PTEN negatively regulates the expression of immunosuppressive cytokines by inhibiting the PI3K pathway.
STAT3 is necessary for transcriptional upregulation of immunosuppressive cytokines in PTEN-deficient cells To further elucidate the mechanism by which PTEN transcriptionally regulates immunosuppressive cytokines, we analyzed the role of the transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kB (NF-kB). We choose STAT3 and NF-kB, because a large number of studies indicate that these transcription factors regulate a variety of cytokines. [15] [16] [17] Moreover, previous studies have also shown that the PI3K pathway can regulate STAT3 and NF-kB. 18, 19 Collectively, these studies suggest that STAT3 and NF-kB might have an important role in the regulation of immunosuppressive cytokine transcription. Therefore, we knocked down STAT3 and NF-kB expression in SKMEL-28 cells using short hairpin RNAs (shRNAs; Figures 2a, b, e and f) and monitored the expression of IL-10, IL-6 and VEGF. Our results showed that shRNA-mediated knockdown of STAT3 inhibited IL-10, IL-6 and VEGF expression (Figures 2c and  d) . However, shRNA-mediated knockdown of NF-kB did not affect the expression of these immunosuppressive cytokines (Figures 2g  and h ), indicating that NF-kB is not necessary for the transcription of these genes in the melanoma cells.
Next, we tested whether STAT3 directly regulates the expression of these genes. To test this, we used the bioinformatics transcription factor-binding site prediction program rVista 2.0 (Loots and Ovcharenko 20 ) and analyzed the promoter regions of the IL-10, IL-6 and VEGF genes from the transcription start site to 5 kb upstream for potential STAT3-binding sites. These analyses revealed potential STAT3-binding sites in the IL-10, IL-6 and VEGF promoter sequences (Figure 3a) . Transcriptional activity of the STAT3 gene is regulated via modulation of STAT3 phosphorylation and nuclear localization. 21, 22 Therefore, we asked whether the PI3K pathway affects STAT3 phosphorylation and/or its nuclear localization. To determine this, we treated SKMEL-28 cells with PI3K inhibitor LY294002. Our results show that inhibition of the PI3K pathway inhibited phosphorylation of STAT3 (Figure 3b ). However, we did not observe any effect of PI3K pathway inhibition on STAT3 cellular localization, and noted that STAT3 was predominantly localized to the nucleus before and after LY294002 treatment (Figure 3c ). In support of our results, previous studies have shown that STAT3 phosphorylation is not necessary for nuclear localization; rather, it regulates the DNA-binding ability of STAT3. 22, 23 Finally, to confirm that the predicted STAT3-binding sites in the IL-6, IL-10 and VEGF promoters are functional and that STAT3 binds to these sites to activate transcription in vivo, we treated SKMEL-28 cells with the PI3K inhibitor LY294002 or dimethylsulfoxide (as a control) and performed chromatin immunoprecipitation experiments. We observed enrichment of STAT3 on IL-10, IL-6 and VEGF promoters in control SKMEL-28 cells that were treated with dimethylsulfoxide ( Figure 3d ). However, upon treatment with the PI3K inhibitor LY294002, STAT3 binding to these promoters was inhibited (Figure 3d) . Collectively, these results show that in PTEN-deficient cells, PI3K pathway activates STAT3, which in turn is required for activating the transcription of immunosuppressive cytokines (Figure 3e ).
Conditioned media from melanoma cells lacking PTEN exerts an immunosuppressive effect As we found that loss of PTEN expression in melanoma cells increases the expression of immunosuppressive cytokines, we examined whether conditioned media derived from PTEN wildtype and PTEN-deficient melanoma cell lines exerts an immunosuppressive effect. To test this, we used the CD14 þ human monocytes-derived dendritic cell model. CD14 þ human monocytes were isolated from the peripheral blood mononuclear cells and differentiated into dendritic cells. We subjected the dendritic cells to maturation by adding Toll-like receptor ligand lipopolysaccharide. Cultures were left untreated or were pretreated with conditioned media derived from melanomas that either express or lack PTEN, and were monitored for IL-12 levels. Notably, the addition of conditioned media from the melanoma cell line lacking PTEN to monocyte-derived dendritic cells inhibited the ability of these cells to secrete the inflammatory cytokine IL-12 (Figures 4a and b) . However, conditioned media derived from two other short-term melanoma cultures that express PTEN did not significantly affect IL-12 secretion by mature dendritic cells. To further confirm the role of PTEN in this process, we used SKMEL-28/PTEN Tet-OFF cells and analyzed the effect of conditioned media obtained under PTEN-expressing and PTEN-deficient conditions on IL-12 production by dendritic cells. In agreement with our earlier results, conditioned media collected from SKMEL-28 cells grown in the presence of doxycycline (PTEN-deficient condition) inhibited IL-12 levels, whereas removal of doxycycline (PTEN-expressing condition) did not affect the ability of dendritic cells to secrete IL-12 ( Figure 4c ). To confirm the role of immunosuppressive cytokines in mediating the immunosuppressive effect due to the PTEN deficiency, we neutralized the expression of IL-6, IL-10 and VEGF by using antibodies in conditioned media collected from PTEN-deficient YUGEN8 cells. We tested the After 24 h, total RNA was prepared and the expression of IL-6, IL-10 and VEGF were analyzed using quantitative reverse transcriptase-PCR (qRT-PCR) analyses. Actin was used as an internal control (b) and protein concentrations were analyzed by ELISA assay (c). (d) SKMEL-28 cells were treated with dimethylsulfoxide (DMSO) or LY294002 (10 mM) for 48 h and indicated proteins were analyzed by immunoblot. (e and f ) SKMEL-28 cells were treated with DMSO or LY294002 (10 mM) for 48 h and the expression of IL-10, IL-6 and VEGF were evaluated using qRT-PCR analyses. Actin was used as an internal control (e) and protein concentrations were analyzed by ELISA assay (f ). (g) Indicated cell lines expressing either an empty vector or Flag-PTEN and immunoblot was performed with Flag or Actin antibody. (h and i) IL-10, IL-6 and VEGF expression was evaluated in indicated cell lines using qRT-PCR analyses. Actin was used as an internal control (h) and protein concentrations were analyzed by ELISA (i). (j) Indicated cell lines were treated with DMSO or LY294002 (10 mM) and were analyzed for p-AKT, total-AKT and actin by immunoblot. (k-l) Indicated cell lines were treated with DMSO or LY294002 (10 mM) for 48 h and the expression of IL-10, IL-6 and VEGF were evaluated using qRT-PCR analyses. Actin was used as an internal control (k) and protein concentrations were analyzed by ELISA assay (l).
immunosuppressive cytokine-neutralized conditioned media or control media to determine the effect on IL-12 production by mature dendritic cells. Remarkably, neutralization of IL-6, IL-10 or VEGF partially rescued IL-12 production by mature dendritic cells (Figure 4d ), confirming the important role of these immunosuppressive cytokines in mediating immune suppression function upon PTEN loss in melanoma. In addition, to confirm the generality of our observations we also analyzed two isogenic cell lines, UACC62 and A2058, that are PTEN-deficient, but are engineered to constitutively express PTEN (Figure 1g ). The results presented in Figure 4e show that conditioned media collected from the PTEN-deficient cells inhibited the ability of dendritic cells to secrete IL-12. However, ectopic expression of PTEN largely rescued this phenotype. Finally, we analyzed two additional melanoma cell lines that were PTEN wild type and expressed a non-specific shRNA or shRNAs targeting PTEN (Figures 4f and g ). In further support of our results, we found that conditioned media collected from the cells expressing PTEN shRNAs exerted a stronger immunosuppressive effect as demonstrated by substantially lower IL-12 production by dendritic cells following lipopolysaccharide treatment (Figures 4f and g ). Collectively, these results document that melanoma cells lacking PTEN exert strong immunosuppressive effects and PTEN expression alone is sufficient to rescue the immune evasion phenotype in melanoma cells.
PTEN downregulates the expression of the immunosuppressor PD-L1 in melanoma cells
To further elucidate additional mechanisms by which PTEN might regulate host immune response, we evaluated the expression of PD-L1 (also known as B7-H1) in melanoma cells. PD-L1 has been shown to have a major role in suppressing host immune response, thereby causing tumor cells to evade the immune response. 24 Formation of the PD-1 receptor/PD-L1 ligand complex transmits an inhibitory signal, which reduces proliferation of antigen-specific CD8 þ T cells at the lymph node. 24 Our experiments were further guided by a previous study in the glioma, which showed that PTEN might have a role in the regulation of PD-L1 expression and immune evasion. 25 Therefore, to test whether PTEN regulates PD-L1 expression in melanoma cells, we analyzed PD-L1 expression in patient-derived, short-term melanoma cultures that either express PTEN (YUVON and YUHEF cells) or lacked PTEN expression (YUGEN8 cells). Our results show that PD-L1 expression inversely correlates with PTEN expression (Figure 5a ). To further confirm that PTEN regulates PD-L1 expression, we knocked down PTEN expression in YUVON and LOX IMVI cells (PTEN wild type) using two different lentiviral PTEN shRNAs and a non-specific shRNA as a control (Figures 4f and g ). After confirming PTEN knockdown, we monitored PD-L1 expression by using flow cytometry analyses. Similar to the results obtained with naturally occurring PTENdeficient short-term melanoma cultures, we noted an increased expression of PD-L1 in YUVON and LOX IMVI cells after shRNAmediated inhibition of PTEN expression (Figures 5b and c) . These results document that PTEN is necessary to repress PD-L1 expression in melanoma cells, which explains in part why PTEN loss might allow melanoma cells to evade the host immune response. To further confirm whether PTEN is sufficient to block PD-L1 expression, we used the SKMEL-28/PTEN Tet-OFF cell line.
We analyzed PD-L1 expression using flow cytometry in SKMEL-28/ PTEN Tet-OFF cells, which were grown in various concentrations of tetracycline. The results presented in Figure 5d show that re-expression of PTEN inhibits PD-L1 expression in SKMEL-28 cells, confirming that re-expression of PTEN is sufficient to block PD-L1 expression in melanoma cells. Finally, to establish whether PTEN overexpression in PTEN-deficient cells lines is sufficient to inhibit PD-L1 expression, we analyzed UACC62 and A2058 cell lines, which are deficient in PTEN, but are engineered to constitutively express PTEN (Figure 1g) . The results presented in Figures 5e and f show that PTEN expression is sufficient to downregulate PD-L1 expression. Collectively, these results establish that PTEN is both necessary and sufficient to regulate PD-L1 expression. However, we cannot rule out the possibility that there might be some scenarios, where PD-L1 regulation might be more complex and require additional genetic or epigenetic factors.
Simultaneous inhibition of the PI3K and BRAF-MEK-ERK pathways enhances the immune response against melanoma cells As a large percentage of melanomas that lack PTEN expression are also BRAF mutant, and previous studies have shown that the activated BRAF pathway may have a role in the regulation of host immune response, [26] [27] [28] we asked whether the PI3K and BRAF-MEK-ERK pathways can be simultaneously inhibited to achieve a stronger immune response. To determine this, we used the BRAF mutant cell line SKMEL-28/PTEN-TET-OFF, and the BRAF mutant and PTEN-deficient UACC62 cell line that was engineered to express either an empty vector or PTEN cDNA (Figure 1g ). We treated these cells with a PI3K inhibitor and a mitogen-activated protein kinase inhibitor, alone or together (Supplementary Figure 1) . We found that the combination treatment was more effective in inhibiting the expression of immunosuppressive cytokines than either drug alone (Figures 6a, b, e and f) . Likewise, the production of IL-12 was more effectively rescued by simultaneous inhibition of the PI3K and BRAF-MEK-ERK pathways (Figures 6c and g ). However, we failed to see any synergistic effect of simultaneous inhibition of the PI3K and mitogen-activated protein kinase pathways on the expression of PD-L1 (Figure 6d (a) Indicated cell lines were analyzed for PTEN expression using immunoblot analyses. Actin was used as a loading control. (b) Conditioned media was collected from indicated cell lines and added on the dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay. Untreated mature CD14 þ monocytederived dendritic cells were used as a control (c). SKMEL-28/Tet-OFF cells were grown with ( þ ) or without ( À ) doxycycline. Conditioned media collected from these two conditions was used to treat dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay. Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control (d). Conditioned media that was pretreated with IgG or neutralizing antibodies against IL-10, IL-6 or VEGF was collected and used to treat dendritic cells at the final volume of 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay. Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control. (e) Conditioned media was collected from indicated cell lines and added on to the dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay. Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control. (f ) YUVON cells expressing indicated shRNAs were analyzed for PTEN and actin expression by immunoblotting (left). Conditioned media was collected from YUVON cells expressing indicated shRNAs and added on to the dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay (right). Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control. (g) LOX IMVI cells expressing indicated shRNAs were analyzed for PTEN and actin expression by immunoblotting (left). Conditioned media was collected from LOX IMVI cells expressing indicated shRNAs and added on to the dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay (right). Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control.
in patient-derived samples, we also examined PTEN expression in malignant melanoma samples with or without a brisk host response. We analyzed 33 malignant melanoma samples with brisk host responses and 34 malignant melanoma samples without brisk host responses, and the brisk host response was confirmed by CD3 staining (Supplementary Table 1 ) and additional dermatopathology information for all the samples is presented in Supplementary Table 2. To ascertain whether PTEN loss correlates with host immune response, we evaluated PTEN expression immunohistochemically in a total of 67 malignant melanoma samples. Our results indicate that the frequency of brisk host response samples with PTEN expression (22 out of 33; 66.66%) was 1.5 times higher compared with the non-brisk response samples (15 out of 34; 44.1%). These results confirmed our in vitro results in a clinical setting and document PTEN as an important regulator of host immune response in human melanoma samples (Figure 7 and Supplementary Tables 1 and 3 ).
Melanomas harbor mutations in the BRAF and RAS genes, which leads to activation of the BRAF-MEK-ERK pathway and the downstream RAS signaling pathway. [29] [30] [31] [32] Moreover, a large percentage of PTEN-mutant melanomas also harbor BRAF or RAS mutations. Therefore, we decided to analyze the mutation status of BRAF and RAS and the role of these mutations in host immune response. Our results showed a lack of any significant correlation between the mutations in the BRAF, KRAS or NRAS genes, and the brisk host response in malignant melanoma (Supplementary Table 4 ).
Statistical modeling to predict the utility of PTEN for classifying brisk and non-brisk host responses in malignant melanoma To assess the dependence of brisk and non-brisk host responses on PTEN expression, we used cross validation, which is a robust approach for model assessment. We used the machine-learning package WEKA 33 and constructed logistic regression models similar to the ones described above. The model was trained and tested using a 10-fold cross-validation approach. The models can be assessed using different criteria, as shown in Table 1 . The results indicate that the PTEN univariate model is robust, because it has more criteria that have better scores. In addition, area under receiver operating characteristic (AUCROC) in the operative point (or the balanced accuracy defined as
is higher in terms of PTEN in the univariate model. We tested other families of classifiers, including naive Bayes, k nearest neighbors, support vector machines and random forest, and found that PTEN can predict brisk host responses in a subset of malignant melanomas.
The results of these analyses are presented in Table 1 . In summary, PTEN alone is sufficient to correctly classify brisk and non-brisk host responses in more than 61% of cases.
DISCUSSION
A well-established, cell non-autonomous tumor suppressive effect that is crucial for the development and progression of various types of human cancers is the host immune response. 8, 34 The ability of a tumor cell to survive and proliferate is, to a large extent, driven by its ability to strategize ways to evade the immune response. The variability of tumors to evade the host immune (g) Conditioned media was collected from UACC62 cells treated with indicated chemical inhibitors at 10 mM for 48 h under indicated conditions and added on to the dendritic cells as 20% of the total growth media. Secreted IL-12 levels were measured using ELISA assay. Untreated mature CD14 þ monocyte-derived dendritic cells were used as a control. *P-valueo0.01 and **P-valueo0.001.
response partially explains the different responses to various immunotherapies. Given the limited information regarding this response in malignant melanoma, we tested the role of PTEN in regulating the host immune response. Loss of PTEN function because of mutation or deletion has been observed in up to one-third of cutaneous melanoma. 2, 35 The results from our experiments reveal that PTEN negatively regulates the expression of immunosuppressive cytokines, including IL-6, IL-10 and VEGF. We show that PTEN-deficient melanoma cells express IL-6, IL-10 and VEGF in a PI3K pathway-dependent manner, which, in a STAT3-dependent manner, activates the transcription of these immunosuppressive cytokines. We also show that PTEN-mediated regulation of immunosuppressive cytokines in melanoma cells is important for regulating the ability of dendritic cells to produce inflammatory cytokine IL-12, which is an indication of host immune response. As an additional and potentially alternative mechanism, we determined that PTEN was both necessary and sufficient to repress the expression of PD-L1, a potent immunosuppressive ligand. 24 Finally, analyses of malignant melanoma samples with or without brisk host responses showed that loss of PTEN was observed in a higher percentage of melanoma samples without brisk host responses. Collectively, these results provide a potential mechanism by which PTEN loss allows melanoma cells to evade the immune response and promote melanoma growth and metastasis.
Our results advance the understanding of melanomagenesis for several reasons. First, we identify PTEN as a molecular biomarker that, in a select subset of patients, predicts brisk host responses. Second, immune-based therapies provide therapeutic benefits in only a subset of melanoma patients, but the reason for the differential response is unknown. Our results provide an opportunity to test PTEN as a molecular biomarker in an effort to identify and recruit melanoma patients that might respond better to immunotherapies. Finally, our results indicate that PTEN might promote host immune responses against cancer cells by repressing the expression of immunosuppressive cytokines and PD-L1 (Figure 8 ). In conclusion, we show that PTEN functions as a melanoma tumor suppressor, in part, by regulating the host immune response to melanoma cells. However, it is likely that additional genetic and epigenetic alterations exist that, similar to PTEN, can regulate host immune response against melanoma cells. Further unbiased, genome-scale analyses are needed to discover and validate these factors.
MATERIALS AND METHODS
Cell culture SKMEL-28 cells were obtained from American Type Culture Collection and grown in RPMI 1640 (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 1 Â penicillin/streptomycin at 37 1C with 5% CO 2 concentrations. SKMEL-28/PTEN-Tet-OFF cells were a kind gift from Dr Charis Eng (Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA) and were maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum, 1 Â penicillin/streptomycin and 1.0 mg/ml doxycycline at 37 1C with 5% CO 2 . Short-term melanoma cultures YUVON, YUHEF and YUGEN8 cells were obtained from the Yale SPORE in Skin Cancer and grown in OPTI-MEM (Invitrogen) supplemented with 5% fetal bovine serum (Invitrogen) and 1 Â penicillin/streptomycin (Invitrogen) at 37 1C with 5% CO 2 .
Lentiviral shRNAs, plasmids, lentivirus production and generation of stable cell lines Lentiviral shRNA against PTEN, NF-kB and STAT3 were obtained from OpenBiosystems (Pittsburgh, PA, USA). shRNA details are presented in Supplementary Table 5 . Flag-PTEN cDNA was obtained from Dr Hong Wu, UCLA, Los Angeles, CA, USA. Lentivirus particles were produced by cotransfecting lentiviral packaging plasmids into 293T cells using the Effectene reagent (Qiagen, Valencia, CA, USA). YUVON cells were infected with PTEN shRNAs and SKMEL-28 cells were infected with STAT3 and NF-kB lentiviral shRNA particles. After infection with lentivirus shRNA particles, cells stably transduced with lentiviral DNA were selected in media containing 0.5 mg/ml puromycin.
PCR and quantitative reverse transcriptase-PCR analyses
Total RNA was extracted using TRIzol reagent (Invitrogen) and purified using RNAeasy mini columns (Qiagen). First-strand cDNA was generated using the ProtoScript M-MuLV First-Strand cDNA Synthesis Kit (New England Biolabs, Ipswich, MA, USA), and quantitative PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems, Grand Island, NY, USA). IL-6, IL-10 and VEGF expression, as well as PTEN, STAT3 and NF-kB knockdown efficiency, were confirmed using quantitative reverse transcriptase-PCR. Primer sequences are listed in Supplementary Table 5 . Actin mRNA was used as an internal control.
Immunoblotting, fractionation, fluorescence-activated cell sorting analyses, ELISA and genotyping Immunoblot analyses were performed as described previously. 36 Protein concentration was estimated using a Bradford Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Blots were developed using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Antibody information is provided in Supplementary Table 5 . Nuclei and cytoplasm were fractionated essentially as described. 37 Protein concentrations were estimated using a Bradford Protein Assay Kit (BioRad Laboratories). Fluorescence-activated cell sorting analyses were performed as described previously, 38 using the anti-B7-H1 antibody and a secondary anti-goat Alexa488 antibody (Jackson Laboratory, Bar Harbor, ME, USA). After staining, samples were analyzed on fluorescence-activated cell sorting Calibur (BD Biosciences, San Jose, CA, USA). Data analyses and calculation of mean fluorescence intensities were performed using FlowJo software. Enzyme-linked immunosorbent assays (ELISA) for IL-6 and IL-10 were performed using kits from BD Biosciences and ELISA assay for VEGF was performed using a kit from Pierce (Thermo Scientific, West Palm Beach, FL, USA). Genotyping of the samples were done as described previously.
39
CD14 þ cell isolation, monocyte-derived dendritic cell induction and maturation, and IL-12 ELISA Buffy coat was obtained from the New York Blood Bank and peripheral blood cells were isolated using Ficoll's gradient. Briefly, buffy coat, saline and 2% methylcellulose were gently mixed and allowed to incubate at room temperature. The supernatant was collected and centrifuged at 1500 r.p.m. for 10 min. The pellet was washed with saline, suspended in complete media and under layered with Ficoll-Paque (GE Healthcare, PIttsburgh, PA, USA). After centrifugation, the interface fraction is collected, centrifuged and washed with MACS buffer. The pellet was suspended in MACS buffer and mixed with anti-CD14 MACS beads to purify CD14 þ monocytes. CD14 þ cells were purified using MACS columns, pelleted and suspended in complete media. For dendritic cell induction, CD14 þ cells were supplemented with a cytokine cocktail that included 100 ng/ml granulocyte-macrophage colony-stimulating factor and 50 ng/ml IL-4 in complete media with or without conditioned media obtained from cells grown under various conditions. On day 5 of culture, 100 ng/ml lipopolysaccharide was added for maturation of DCs. On day 6, the culture supernatant was collected and IL-12 levels were analyzed using ELISA assay. IL-12 ELISA assays were performed using the human IL-12 p70 ELISA Ready-Set-Go! reagent set (eBiosciences, San Diego, CA, USA).
Sample selection for clinical study
The human subject studies were approved by the Boston University School of Medicine Institutional Review Board (IRB docket numbers H-29085 and H-29501). Archival materials from 2000 to 2010 with a diagnosis of primary cutaneous malignant melanoma were retrieved from the pathology files of the Skin Pathology Laboratory, Boston University School of Medicine (Boston, MA, USA). In this study, the genetic heterogeneity of primary cutaneous melanoma excluded melanomas occurring on acral and/or mucosal surfaces. A total of 33 formalin-fixed, paraffin-embedded primary cutaneous malignant melanomas with an associated brisk host response were identified and included in the study. A brisk host response was defined as a dense band of lymphocytes among tumor cells across the entire base or throughout the tumor as previously described. The control group were primary cutaneous melanomas (n ¼ 34) without a brisk host response. Histologic sections from all cases were re-reviewed and the diagnoses confirmed by a dermatopathologist (MM and PPA). All patient data were de-identified. The patient demographics are detailed in Supplementary Table 1 . To confirm the quality of the melanoma samples, we performed CD3 immunohistochemistry on brisk and non-brisk response samples 41 (Supplementary Table 1 and Figure 7 ).
Immunohistochemistry
Immunohistochemistry was performed as described previously 36 using antibodies against PTEN (clone 6H 2.1, Millipore, Billerica, CA, USA) and CD3 (clone F7.2.38, Dako, Carpinteria, CA, USA). Appropriate positive and PTEN regulates host immune response Y Dong et al negative controls were used. Positive staining was noted by PTEN and CD3 expression in the cytoplasm. Significant nuclear staining was not observed with any of the antibodies. All stained slides were initially reviewed and scored by a dermatopathologist (MM) in a blinded fashion (with respect to genotype) to ensure consistent interpretation. For PTEN immunohistochemical staining, lesional melanocytes were scored as negative (o20% of tumor cells stained), intermediate (20-79% of tumor cells stained) and diffuse (480% of tumor cells stained). Cases with intermediate staining were considered positive for purposes of statistical analyses. For CD3 immunohistochemical staining, lesional lymphocytes were scored as negative (o20% of tumor cells stained), intermediate (20-79% of tumor cells stained) and diffuse (480% of tumor cells stained). Cases with intermediate staining were considered positive for purposes of statistical analyses. Each slide was also reviewed independently by two dermatopathologists (MM and PPA) and disagreements were resolved by discussion to achieve a consensus score.
Statistical analyses
All experiments were performed at least three times. Mean values for individual experiments are expressed as the mean ± s.e.m. The s.e.m. and P-values were calculated using Microsoft excel and GraphPad Prism version 6.02 for Machintosh, GraphPad Software, San Diego, CA, USA (www.graphpad.com).
